FFX-news

2022.09.28-2022.09.30 – FFX as industry sponsor at dgfz-meeting 2022

For the first time since FFX was founded in May 2020, we were able to participate ‘offline’ to the Annual Conference of the German Society of Cytometry as an industry sponsor – proudly teaming up with Rivercyte!

2022.09.28-2022.09.30 – German Society of Cytometry

Following this year’s motto “Spotlight on cells: life style and environment”, DGfZ strives to bring together experts from various disciplines for a lively discussion about game-changing technologies and their newest applications.   We want to see you all in Berlin!

2022.04.18 – The Ecosystem Company

As one of Rhein-Neckar’s Biotech-StartUps, FFX knows about the value of a supportive and prosperous enviroment. So we are proud to be present on the latest regional poster of ‘It takes a Region’.

2022.03.22 – MPL

In a fireside chat, Felix Dirla, CEO of FFX, gave the participants of the talent development programme “Light up your career” at the Max Placnk Institute for the Science of Light an insight into the world of innovative emerging spin-offs.

2021.12.01 – WWT

As of December 2021, FFX assigns Worldwide Technologies (S.H.) Co., Ltd. as its exclusive distributor for the TissueGrinder technology in China.

2022.10.19 – bwcon

FFX was chosen as one of three finalists in the category Life Science & Health Care at the CyberOne Hightech Award bwcon.

2021.10.05 – CUBEX41

FFX’ TissueGrinder consumables are now available in a sterile configuration. Individually sealed in a Tyvek flow pack, the entire set is treated with vaporized H2O2 plasma.

2021.05.20 – q&more

In q&more, Dr. Jens Langejürgen and Stefan Scheuermann explain how the future of health diagnostics begins at the level of the individual cell.

Faster to single cells using miniature grinder

2021.03.10 – BIOPRO

BIOPRO features the FFX TissueGrinder in their dossiers on Cancer therapy/diagnostics and Disease prevention through better diagnostics.

Keine Moulinette - FFX Company Portrait

2021.02.09 – LABORJOURNAL

In its January/February edition 2021, LABORJOURNAL features a portrait of how FFX is starting up to commercialize the TissueGrinder technology.

Die Gewebe-Spalter - Press release

2020.09.30 – Fraunhofer IPA

FFX commercializes the TissueGrinder technology developed at Fraunhofer IPA – unlocking the door to innovations in personalized medicine.